A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

Summary

This study evaluates the effect of pembrolizumab on the duration of remission in acute myeloid leukemia. Pembrolizumab is given after complete remission is obtained in those with AML at least 60 years old who are not candidates for allogeneic stem cell transplant. The primary purpose of this study is determine if the time to relapse can be extended. Additionally, the safety and tolerability of pembrolizumab will be closely monitored.

Timeline

Start

2016-10-04

Primary completion

2020-06-11

Completion

2020-12

Drugs

Indications